Portal de Periódicos da CAPES

Transcatheter Mitral Valve Therapy in the United States

2021; Elsevier BV; Volume: 78; Issue: 23 Linguagem: Inglês

10.1016/j.jacc.2021.07.058

1558-3597

Michael J. Mack, John D. Carroll, Vinod H. Thourani, Sreekanth Vemulapalli, John J. Squiers, Pratik Manandhar, G. Michael Deeb, Wayne Batchelor, Howard C. Herrmann, David J. Cohen, George Hanzel, Thomas G. Gleason, Ajay J. Kirtane, Nimesh D. Desai, Kim Guibone, Karen M. Hardy, Joan Michaels, J. Michael DiMaio, Barbara L. Christensen, Susan Fitzgerald, Carole Krohn, Ralph G. Brindis, Fred Masoudi, Joseph E. Bavaria,

Cardiac pacing and defibrillation studies

Data for nearly all patients undergoing transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement (TMVR) with an approved device in the United States is captured in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. All data submitted for TEER or TMVR between 2014 and March 31, 2020, are reported. A total of 37,475 patients underwent a mitral transcatheter procedure, including 33,878 TEER and 3,597 TMVR. Annual procedure volumes for TEER have increased from 1,152 per year in 2014 to 10,460 per year in 2019 at 403 sites and for TMVR from 84 per year to 1,120 per year at 301 centers. Mortality rates have decreased for TEER at 30 days (5.6%-4.1%) and 1 year (27.4%-22.0%). Early off-label use data on TMVR in mitral valve-in-valve therapy led to approval by the U.S. Food and Drug Administration in 2017, and the 2019 30-day mortality rate was 3.9%. Overall improvements in outcomes over the last 6 years are apparent. (STS/ACC TVT Registry Mitral Module; NCT02245763)